Indication
Hemostatic Disorder
1 clinical trial
1 product
Product
CYNK-001Clinical trial
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.Status: Active (not recruiting), Estimated PCD: 2023-01-31